Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

New GPR119 receptor agonists claimed

Nov. 7, 2011

FDA accepts VIVUS' resubmitted Qnexa NDA

Nov. 4, 2011

Korean company patents new glucagon GLP-1 receptor agonists

Nov. 4, 2011

Clinuvel's Scenesse shows clinically relevant prophylactic effect in EPP

Nov. 4, 2011

Isis antisense drugs enter phase I development for type 2 diabetes

Nov. 3, 2011

FDA sets PDUFA date for alogliptin and alogliptin/pioglitazone NDAs

Nov. 3, 2011

Promising data disclosed from phase Ib trial of DB-959Na

Nov. 3, 2011

Novel sterol O-acyltransferase 2 inhibitors synthesized in Japan

Nov. 2, 2011

Novel diacylglycerol O-acyltransferase type 1 inhibitors synthesized by AstraZeneca

Oct. 31, 2011

Novel tachykinin NK3 receptor antagonists claimed by Euroscreen

Oct. 31, 2011

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 5, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Axsome’s Auvelity cleared for large Alzheimer’s agitation market
BioWorld
Axsome Therapeutics Inc. won U.S. FDA approval for Auvelity (AXS-05) to treat Alzheimer’s disease agitation, a condition that affects up to three-quarters of...
Cytospire raises £61M series A to target EGFR in solid tumors
BioWorld
Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance...
Bio Korea 2026: US policy risks shift to execution framework
BioWorld
Regulatory uncertainty that dominated the life science sector in 2025 is transitioning into an execution framework for biotechnology companies, provided companies...